Defunct Company
Total Trials
30
As Lead Sponsor
25
As Collaborator
5
Total Enrollment
7,322
NCT00041925
Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures
Phase: Phase 2/3
Role: Lead Sponsor
Start: Nov 30, 2001
Completion: Nov 30, 2004
NCT00042081
Prevention of Autogenous Vein Graft Failure in Coronary Artery Bypass Procedures
Phase: Phase 3
Start: Jul 31, 2002
Completion: Feb 28, 2005
NCT00086164
Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis
Phase: Phase 1/2
Start: May 31, 2004
Completion: Not specified
NCT00125333
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
Start: Mar 31, 2005
Completion: Nov 30, 2005
NCT00681356
Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement
Start: Sep 30, 2007
Completion: Dec 31, 2008
NCT00683267
Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement
Phase: Phase 2
NCT00656578
Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy
Start: Mar 31, 2008
Completion: Sep 30, 2008
NCT00672568
Safety and Tolerability of 4975 in Patients Undergoing Arthroscopic Surgery to Repair the Rotator Cuff of the Shoulder
Start: Jul 31, 2008
NCT00766181
Satisfaction With Pediatric Intravenous Catheter Placement in the Emergency Department
Phase: N/A
Start: Oct 31, 2008
Completion: Apr 30, 2009
NCT01293552
Clinical Trial To Evaluate ANT-1207 In Subjects With Acne
Start: Jan 31, 2011
Completion: Jul 31, 2012
NCT01358695
Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet
Start: May 31, 2011
Completion: May 31, 2012
NCT01799824
Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis
Start: Feb 28, 2013
Completion: Jul 31, 2013
NCT01809964
Clinical Trial to Evaluate ANT-1401 in Crow's Feet
Start: Mar 31, 2013
Completion: Oct 31, 2013
NCT01951742
Dose Finding Study In Subjects With Crow's Feet
Start: Sep 30, 2013
Completion: Jan 31, 2014
NCT03888612
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
Start: Mar 1, 2019
Completion: Jan 27, 2025
NCT05201911
A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis
Phase: Phase 1
Start: Nov 30, 2021
Completion: Sep 6, 2022
NCT05235269
A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis
Completion: Feb 24, 2023
NCT05285735
Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants
Start: Jun 8, 2022
Completion: Jul 1, 2029
NCT05635045
Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR
Role: Collaborator
Start: Jul 8, 2022
Completion: Jun 12, 2024
NCT05521022
Study of AT-02 in Healthy Volunteers and Subjects With Systemic Amyloidosis
Start: Sep 1, 2022
Completion: Mar 1, 2025
NCT05758493
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Start: Jan 10, 2023
Completion: Mar 10, 2028
NCT05549505
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Start: Feb 15, 2023
Completion: Jul 25, 2024
NCT05951816
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Start: Jul 31, 2023
Completion: Dec 31, 2025
NCT05951049
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Start: Sep 21, 2023
Completion: Feb 28, 2026
NCT06393738
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Start: Sep 5, 2024
NCT06555809
Evaluation of Artesunate in Infants Being Treated for Severe Malaria
Start: Oct 6, 2024
Completion: Feb 28, 2030
NCT06788535
Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis
Start: Jan 14, 2025
NCT07023731
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Start: May 29, 2025
Completion: Apr 2, 2029
NCT06907849
124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome
Start: May 31, 2025
Completion: May 31, 2027
NCT06853184
Study Evaluating the Efficacy and Safety of Artesunate
Start: Aug 1, 2025
Completion: Jun 30, 2028